<?xml version="1.0" encoding="UTF-8"?>
<p>The clinical implications of MR results are not always straightforward, as is illustrated by an MR study about body mass index (BMI) and Parkinson’s disease. Observational evidence has been conflicting (
 <xref rid="fcaa031-B95" ref-type="bibr">Wang 
  <italic>et al.</italic>, 2015
 </xref>; 
 <xref rid="fcaa031-B97" ref-type="bibr">Wills 
  <italic>et al.</italic>, 2016
 </xref>; 
 <xref rid="fcaa031-B77" ref-type="bibr">Roos 
  <italic>et al.</italic>, 2018
 </xref>), and an MR study found that genetically higher BMI is protective against Parkinson’s disease (
 <xref rid="fcaa031-B68" ref-type="bibr">Noyce 
  <italic>et al.</italic>, 2017
 </xref>). Current MR methods detect 
 <italic>whether</italic> there is a causal relationship, rather than the 
 <italic>magnitude</italic> thereof, so it is not clear how much of a BMI change would be needed to influence Parkinson’s disease risk. Given that a raised BMI is a well-established risk factor for cardiovascular disease (
 <xref rid="fcaa031-B9" ref-type="bibr">Benjamin 
  <italic>et al.</italic>, 2019
 </xref>), promoting a raised BMI for the sake of Parkinson’s disease protection produces a challenge.
</p>
